Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 13INDUSTRY 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Lymphoid 2Head & Neck 2Gastrointestinal 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1

Conditions

Melanoma 93Carcinoma, Non-Small-Cell Lung 46Neoplasms 33Carcinoma, Renal Cell 24Neoplasm Metastasis 16Colorectal Neoplasms 13Carcinoma, Hepatocellular 12Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Advanced Cancer 9Squamous Cell Carcinoma of Head and Neck 8Uveal Melanoma 7Stomach Neoplasms 7Skin Neoplasms 7Mesothelioma 7Kidney Neoplasms 7Carcinoma, Transitional Cell 7Recurrence 6Pancreatic Neoplasms 6Liver Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Solid Tumor 4

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Ipilimumab × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04132817 2022-12-02

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Bristol-Myers Squibb

Phase 1 Completed
12 enrolled
Breast

Breast Neoplasms

NCT03342417 2021-11-09

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

ExcellaBio LLC

Phase 2 Terminated
5 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Lytix Biopharma AS

Phase 1 Completed
80 enrolled
BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00083278 2012-04-27

Study of MDX-010 in Stage IV Breast Cancer

Bristol-Myers Squibb

Phase 2 Completed
33 enrolled
Breast

Adenocarcinoma, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡